ARQL ArQule, Inc.

1.22
+0  (0%)
Previous Close 1.22
Open 1.22
Price To book 3.66
Market Cap 86.79M
Shares 71,136,000
Volume 49,322
Short Ratio 1.78
Av. Daily Volume 204,623

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment completed. Phase 3 trial planned for 3Q 2017.
ARQ 087
intrahepatic cholangiocarcinoma (iCCA)
Phase 3 top-line data released February 17, 2017 - primary endpoint not met.
Tivantinib (ARQ 197) METIV-HCC trial
Previously treated Inoperable Hepatocellular Carcinoma cancer

Latest News

  1. ArQule, Inc. :ARQL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  2. ARQULE INC Financials
  3. ArQule, Inc. :ARQL-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  4. ARQULE INC Files SEC form 10-K, Annual Report
  5. Edited Transcript of ARQL earnings conference call or presentation 7-Mar-17 2:00pm GMT
  6. ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  7. ArQule reports 4Q loss
  8. ArQule reports 4Q loss
  9. Q4 2016 ArQule Inc Earnings Release - Before Market Open
  10. ArQule Reports Fourth Quarter and Full Year 2016 Financial Results
  11. ArQule To Report Fourth Quarter and Year End 2016 Financial Results On March 7, 2017
  12. ArQule Liver Cancer Drug Fails Phase 3 Trial
  13. ArQule, Inc. (ARQL)’s Liver Cancer Drug Fails: What’s Next?
  14. Sabre Corp., L Brands Dip into Friday’s 52-Week Low Club
  15. ARQULE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  16. Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma
  17. Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma
  18. Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma
  19. ArQule to Present at The Leerink Partners 6th Annual Global Healthcare Conference on February 15, 2017
  20. ArQule (ARQL) Catches Eye: Stock Moves 7.2% Higher